Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Teilo H Schaller"'
Autor:
Andrew L Mammen, Jarushka Naidoo, Divyanshu Dubey, Michael Dougan, Teilo H Schaller, Meghan J Mooradian, Douglas B Johnson, Jorg Dietrich, Leyre Zubiri, Tomas G Neilan, Bianca D Santomasso, Ryan J Sullivan, Kerry L Reynolds, Allison Betof Warner, Justine V Cohen, Nancy Wang, Jenny Linnoila, Jeffrey M Gelfand, Anthony A Amato, Stacey L Clardy, David A Reardon, William C Louv, Amanda C Guidon, Leeann B Burton, Bart K Chwalisz, James Hillis, Priscilla K Brastianos, Tracey A Cho, Christopher T Doughty, Jeffrey T Guptill, Vern C Juel, Robert Kadish, Noah Kolb, Nicole R LeBoeuf, Maria Martinez-Lage, Krista M Rubin, Karin Woodman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence
Externí odkaz:
https://doaj.org/article/a2206707f599451b8603379684ad2015
Autor:
Patrick C Gedeon, Michael A Streicker, Teilo H Schaller, Gary E Archer, Micheal P Jokinen, John H Sampson
Publikováno v:
PLoS ONE, Vol 15, Iss 7, p e0236374 (2020)
We recently reported the development of a fully-human, CD3-binding bispecific antibody for immunotherapy of malignant glioma. To translate this therapeutic (hEGFRvIII-CD3- bi-scFv) to clinical trials and to help further the translation of other simil
Externí odkaz:
https://doaj.org/article/334a6dbbc0df4031bcd8df6d1e46cc04
Autor:
Shawn M. Sweeney, Hisham K. Hamadeh, Natalie Abrams, Stacey J. Adam, Sara Brenner, Dana E. Connors, Gerard J. Davis, Louis D. Fiore, Susan H. Gawel, Robert L. Grossman, Sean E. Hanlon, Karl Hsu, Gary J. Kelloff, Ilan R. Kirsch, Bill Louv, Deven McGraw, Frank Meng, Daniel Milgram, Robert S. Miller, Emily Morgan, Lata Mukundan, Thomas O'Brien, Paul Robbins, Eric H. Rubin, Wendy S. Rubinstein, Liz Salmi, Teilo H. Schaller, George Shi, Caroline C. Sigman, Sudhir Srivastava
Publikováno v:
Cancer Research. 83:1183-1190
The analysis of big healthcare data has enormous potential as a tool for advancing oncology drug development and patient treatment, particularly in the context of precision medicine. However, there are challenges in organizing, sharing, integrating,
Autor:
John H. Sampson, Darell D. Bigner, Luis Sanchez-Perez, Elizabeth A. Reap, Gary E. Archer, Stephen T. Keir, Roger E. McLendon, James E. Herndon, Patrick N. Healy, Xiuyu Cui, Scott E. Szafranski, Robert J. Schmittling, David J. Snyder, Carter M. Suryadevara, Chien-Tsun Kuan, Bryan D. Choi, Satish K. Chitneni, Teilo H. Schaller, Patrick C. Gedeon
Table S2 - Glioma cell lines and patient derived tumor samples used for study with the number of EGFRvIII receptors per cell, the number of EGFRwt receptors per cell and the proportion of cells expressing EGFRvIII in the given cell line or tumor samp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044ccc0bbab6f20d0b58d82dddba22dd
https://doi.org/10.1158/1078-0432.22464450.v1
https://doi.org/10.1158/1078-0432.22464450.v1
Autor:
John H. Sampson, Darell D. Bigner, Luis Sanchez-Perez, Elizabeth A. Reap, Gary E. Archer, Stephen T. Keir, Roger E. McLendon, James E. Herndon, Patrick N. Healy, Xiuyu Cui, Scott E. Szafranski, Robert J. Schmittling, David J. Snyder, Carter M. Suryadevara, Chien-Tsun Kuan, Bryan D. Choi, Satish K. Chitneni, Teilo H. Schaller, Patrick C. Gedeon
Purpose: Conventional therapy for malignant glioma fails to specifically target tumor cells. In contrast, substantial evidence indicates that if appropriately redirected, T cells can precisely eradicate tumors. Here we report the rational development
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c540ead1b7766f857bb8730e93a593d
https://doi.org/10.1158/1078-0432.c.6525723.v1
https://doi.org/10.1158/1078-0432.c.6525723.v1
Autor:
Teilo H. Schaller, John H. Sampson
Publikováno v:
Expert Review of Vaccines, Vol 16, Iss 1, Pp 27-36 (2017)
Introduction: Glioblastoma is the most common primary brain tumor in adults and prognosis remains poor with a median survival of approximately 15–17 months. This review provides an overview of recent advances in the field of glioblastoma immunother
Externí odkaz:
https://doaj.org/article/74e514cb0d6746b99ef8c7ac18825765
Autor:
Kerry L. Reynolds, Elad Sharon, Meghan E. Sise, Douglas B. Johnson, Laura A. Petrillo, William C Louv, Mace L. Rothenberg, Michael Dougan, Sean Khozin, Aakanksha Khandelwal, Teilo H Schaller, Amanda C. Guidon, Shaily Arora, Ravikumar Komandur Elayavilli, Osama E. Rahma, Alexandra-Chloé Villani, Leyre Zubiri
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use o
Autor:
Amanda C. Guidon, Vern C. Juel, William C Louv, Justine V. Cohen, Jenny J. Linnoila, David A. Reardon, Leyre Zubiri, Christopher T. Doughty, Priscilla K. Brastianos, Jeffrey T. Guptill, Jeffrey M. Gelfand, Douglas B. Johnson, Nicole R. LeBoeuf, Divyanshu Dubey, Jorg Dietrich, Andrew L. Mammen, Jarushka Naidoo, Tomas G. Neilan, Anthony A. Amato, Bart K Chwalisz, Robert Kadish, Ryan J. Sullivan, Noah Kolb, Allison Betof Warner, Karin Woodman, Michael Dougan, Nancy Wang, Meghan J. Mooradian, Bianca Santomasso, Teilo H Schaller, Maria Martinez-Lage, Krista M. Rubin, Tracey A. Cho, James M. Hillis, Leeann B Burton, Kerry L. Reynolds, Stacey L. Clardy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence
Autor:
David J. Snyder, John H. Sampson, Teilo H Schaller, Luis Sanchez-Perez, Patrick C. Gedeon, Ivan Spasojevic
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundFirst-in-human (FIH) clinical trials require careful selection of a safe yet biologically relevant starting dose. Typically, such starting doses are selected based on toxicity studies in a pharmacologically relevant animal model. However, w
Autor:
Teilo H Schaller, Bart K Chwalisz, James M. Hillis, Leeann B Burton, Amanda C. Guidon, Neuro irAE Disease Definition Panel, Kerry L. Reynolds
Publikováno v:
Journal of Clinical Oncology. 39:2647-2647
2647 Background: Expanding FDA-approved indications for immune checkpoint inhibitors in patients with cancer has resulted in both therapeutic success and immune related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1-12% and